{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:06:58Z","timestamp":1783980418541,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"29","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA243167"],"award-info":[{"award-number":["CA243167"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA288849"],"award-info":[{"award-number":["CA288849"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA304343"],"award-info":[{"award-number":["CA304343"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Identification and characterization of novel mechanisms driving melanoma metastases and ways to target them are paramount for the development of effective treatment modalities. Here, we employed in vivo CRISPR knockout screening targeting the genes associated with poor prognosis to identify Polr1a as a potent driver of melanoma metastasis. High Polr1a levels correlate with increased metastasis and reduced survival in patients. Polr1a inhibition suppressed migration, invasion, and the ability of melanoma cells to colonize lungs. Ribo-seq analysis revealed that Polr1a is involved in regulating the non-canonical NF-\u03baB pathway. Indeed, targeting Polr1a decreased levels of RelB and p52 and suppressed non-canonical NF-\u03baB transcriptional activity; this suppression was responsible for the effects of Polr1a on melanoma cell migration. Accordingly, pharmacological inhibition of Polr1\/Polr1a suppressed cell migration, tumor growth, and metastases. We discuss the potential utilization of Polr1 inhibitors for neoadjuvant treatment of melanoma.<\/jats:p>","DOI":"10.1038\/s41388-026-03851-4","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:31:19Z","timestamp":1781731879000},"page":"2978-2987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vivo CRISPR knockout screen identifies Polr1a as a key driver and a potential therapeutic target for melanoma metastasis"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0045-1875","authenticated-orcid":false,"given":"Anna F.","family":"Fajardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chethana P.","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek S.","family":"Tomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2301","authenticated-orcid":false,"given":"M.","family":"Andres Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3992-2817","authenticated-orcid":false,"given":"Irina A.","family":"Elcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0136-5103","authenticated-orcid":false,"given":"Serge Y.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-155X","authenticated-orcid":false,"given":"Vladimir S.","family":"Spiegelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"3851_CR1","doi-asserted-by":"publisher","unstructured":"Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. https:\/\/doi.org\/10.1155\/2012\/647684 2012.","DOI":"10.1155\/2012\/647684"},{"key":"3851_CR2","first-page":"572","volume":"1","author":"A Sandru","year":"2014","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;1:572.","journal-title":"J Med Life"},{"key":"3851_CR3","first-page":"488.","volume":"23","author":"S Bhatia","year":"2009","unstructured":"Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview of prognostic factors for metastatic melanoma. Oncology. 2009;23:488.","journal-title":"Oncology"},{"key":"3851_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2340\/00015555-2035","volume":"95","author":"E Maverakis","year":"2015","unstructured":"Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, et al. Metastatic melanoma\u2014a review of current and future treatment options. Acta Derm Venereol. 2015;95:516\u201324. PubMed PMID: 25520039.","journal-title":"Acta Derm Venereol"},{"key":"3851_CR5","first-page":"1","volume":"11","author":"AG Michniewicz","year":"2019","unstructured":"Michniewicz AG, Czyz M. Role of miRNAs in melanoma metastasis. Cancers. 2019;11:1\u201323.","journal-title":"Cancers"},{"key":"3851_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/pcmr.12825","volume":"33","author":"A Nagler","year":"2020","unstructured":"Nagler A, Vredevoogd DW, Alon M, Cheng PF, Trabish S, Kalaora S, et al. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 2020;33:334\u201344.","journal-title":"Pigment Cell Melanoma Res"},{"key":"3851_CR7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","volume":"23","author":"J Dubrot","year":"2022","unstructured":"Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23:1495\u2013506.","journal-title":"Nat Immunol"},{"key":"3851_CR8","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1158\/0008-5472.CAN-21-3217","volume":"82","author":"W Cai","year":"2022","unstructured":"Cai W, Nguyen MQ, Wilski NA, Purwin TJ, Vernon M, Tiago M, et al. A Genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1\/2 inhibitors in NRAS mutant melanoma. Cancer Res. 2022;82:2625\u201339.","journal-title":"Cancer Res"},{"key":"3851_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pgen.1009176","volume":"16","author":"EM Schleicher","year":"2020","unstructured":"Schleicher EM, Dhoonmoon A, Jackson LM, Clements KE, Stump CL, Nicolae CM, et al. Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors. PLoS Genet. 2020;16:1\u201325.","journal-title":"PLoS Genet"},{"key":"3851_CR10","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/cas.15783","volume":"114","author":"ML Jin","year":"2023","unstructured":"Jin ML, Gong Y, Ji P, Hu X, Shao ZM. In vivo CRISPR screens identify RhoV as a pro-metastasis factor of triple-negative breast cancer. Cancer Sci. 2023;114:2375\u201385.","journal-title":"Cancer Sci"},{"key":"3851_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.66222","volume":"10","author":"J Li","year":"2021","unstructured":"Li J, Qin X, Shi J, Wang X, Li T, Xu M, et al. A systematic CRISPR screen reveals an IL-20\/il20ra-mediated immune crosstalk to prevent the ovarian cancer metastasis. Elife. 2021;10:1\u201327.","journal-title":"Elife"},{"key":"3851_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-021-01912-w","volume":"4","author":"L van der Weyden","year":"2021","unstructured":"van der Weyden L, Harle V, Turner G, Offord V, Iyer V, Droop A, et al. CRISPR activation screen in mice identifies novel membrane proteins enhancing pulmonary metastatic colonisation. Commun Biol. 2021;4:1\u201312.","journal-title":"Commun Biol"},{"key":"3851_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675.","journal-title":"Nat Biotechnol"},{"key":"3851_CR14","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12:828\u201363.","journal-title":"Nat Protoc"},{"key":"3851_CR15","doi-asserted-by":"publisher","first-page":"W345","DOI":"10.1093\/nar\/gkac247","volume":"50","author":"E Afgan","year":"2022","unstructured":"Afgan E, Nekrutenko A, Gr\u00fcning BA, Blankenberg D, Goecks J, Schatz MC, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2022 update. Nucleic Acids Res. 2022;50:W345\u201351.","journal-title":"Nucleic Acids Res"},{"key":"3851_CR16","doi-asserted-by":"publisher","first-page":"e0237096","DOI":"10.1371\/journal.pone.0237096","volume":"15","author":"R Van Eenige","year":"2020","unstructured":"Van Eenige R, Verhave PS, Koemans PJ, Tiebosch IACW, Rensen PCN, Kooijman S. RandoMice, a novel, user-friendly randomization tool in animal research. PLoS One. 2020;15:e0237096.","journal-title":"PLoS One"},{"key":"3851_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2013.12.009","volume":"25","author":"K Peltonen","year":"2014","unstructured":"Peltonen K, Colis L, Liu H, Trivedi R, Moubarek MS, Moore HM, et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell. 2014;25:77\u201390.","journal-title":"Cancer Cell"},{"key":"3851_CR18","doi-asserted-by":"publisher","unstructured":"Prakash V, Carson BB, Feenstra JM, Dass RA, Sekyrova P, Hoshino A, et al. Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. Nat Commun. 10. https:\/\/doi.org\/10.1038\/s41467-019-10100-8 2019.","DOI":"10.1038\/s41467-019-10100-8"},{"key":"3851_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA Pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400\u2013416.e11.","journal-title":"Cell"},{"key":"3851_CR20","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/ml300110s","volume":"3","author":"M Haddach","year":"2012","unstructured":"Haddach M, Schwaebe MK, Michaux J, Nagasawa J, O\u2019Brien SE, Whitten JP, et al. Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics. ACS Med Chem Lett. 2012;3:602.","journal-title":"ACS Med Chem Lett"},{"key":"3851_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-31199-2","volume":"13","author":"J Hilton","year":"2022","unstructured":"Hilton J, Gelmon K, Bedard PL, Tu D, Xu H, Tinker AV, et al. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. Nat Commun. 2022;13:1\u201312.","journal-title":"Nat Commun"},{"key":"3851_CR22","doi-asserted-by":"publisher","unstructured":"Ferreira R, Schneekloth JS, Panov KI, Hannan KM, Hannan RD. Targeting the RNA polymerase I transcription for cancer therapy comes of age. Cells. https:\/\/doi.org\/10.3390\/cells9020266 2020.","DOI":"10.3390\/cells9020266"},{"key":"3851_CR23","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/pros.23909","volume":"79","author":"JY Low","year":"2019","unstructured":"Low JY, Sirajuddin P, Moubarek M, Agarwal S, Rege A, Guner G, et al. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer. Prostate. 2019;79:1837\u201351.","journal-title":"Prostate"},{"key":"3851_CR24","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","volume":"9","author":"A Khot","year":"2019","unstructured":"Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, et al. First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study. Cancer Discov. 2019;9:1036\u201349.","journal-title":"Cancer Discov"},{"key":"3851_CR25","doi-asserted-by":"publisher","first-page":"30099","DOI":"10.1074\/jbc.M401428200","volume":"279","author":"G Xiao","year":"2004","unstructured":"Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-\u03baB-inducing kinase involves docking I\u03baB kinase \u03b1 (IKK\u03b1) to p100 and IKK\u03b1-mediated phosphorylation. J Biol Chem. 2004;279:30099\u2013105.","journal-title":"J Biol Chem"},{"key":"3851_CR26","first-page":"1","volume":"8","author":"H Xu","year":"2017","unstructured":"Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O\u2019Neil NJ, et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours. Nat Commun. 2017;8:1\u201318.","journal-title":"Nat Commun"},{"key":"3851_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ggedit.2021.100008","volume":"2","author":"M Kuhn","year":"2021","unstructured":"Kuhn M, Santinha AJ, Platt RJ. Moving from in vitro to in vivo CRISPR screens. Gene Genome Editing. 2021;2:100008.","journal-title":"Gene Genome Editing"},{"key":"3851_CR28","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41388-017-0026-x","volume":"37","author":"S Lv","year":"2018","unstructured":"Lv S, Ji L, Chen B, Liu S, Lei C, Liu X, et al. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene. 2018;37:1354\u201368.","journal-title":"Oncogene"},{"key":"3851_CR29","first-page":"1964","volume":"15","author":"T Yi","year":"2023","unstructured":"Yi T, Peng L, Li P, He Y, Tian J. High expression of KMT2D is a promising biomarker for poor gastric cancer prognosis. Am J Transl Res. 2023;15:1964\u201372.","journal-title":"Am J Transl Res"},{"key":"3851_CR30","doi-asserted-by":"publisher","unstructured":"Dong J, Ru Y, Zhai L, Gao Y, Guo X, Chen B, et al. LMNB1 deletion in ovarian cancer inhibits the proliferation and metastasis of tumor cells through PI3K\/Akt pathway. Exp Cell Res. 426. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113573 2023.","DOI":"10.1016\/j.yexcr.2023.113573"},{"key":"3851_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.yexmp.2015.03.008","volume":"98","author":"YF Zeng","year":"2015","unstructured":"Zeng YF, Xiao YS, Lu MZ, Luo XJ, Hu GZ, Deng KY, et al. Increased expression of formin-like 3 contributes to metastasis and poor prognosis in colorectal carcinoma. Exp Mol Pathol. 2015;98:260\u20137.","journal-title":"Exp Mol Pathol"},{"key":"3851_CR32","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","volume":"82","author":"AR Elhamamsy","year":"2022","unstructured":"Elhamamsy AR, Metge BJ, Alsheikh HA, Shevde LA, Samant RS. Ribosome biogenesis: a central player in cancer metastasis and therapeutic resistance. Cancer Res. 2022;82:2344\u201353.","journal-title":"Cancer Res"},{"key":"3851_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2017","unstructured":"Pelletier J, Thomas G, Volarevi S. Ribosome biogenesis in cancer: New players and therapeutic avenues. Nat Rev Cancer. 2017;18:51\u201363.","journal-title":"Nat Rev Cancer"},{"key":"3851_CR34","doi-asserted-by":"crossref","unstructured":"Gay DM, Lund AH, Jansson MD. Translational control through ribosome heterogeneity and functional specialization. Trends Biochem Sci. 2022;22:66\u201381.","DOI":"10.1016\/j.tibs.2021.07.001"},{"key":"3851_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun SC. The non-canonical NF-\u03baB pathway in immunity and inflammation HHS Public Access. Nat Rev Immunol. 2017;17:545\u201358.","journal-title":"Nat Rev Immunol"},{"key":"3851_CR36","first-page":"71","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun SC. Non-canonical NF-\u03baB signaling pathway. Nat Publ Group. 2011;21:71\u201385.","journal-title":"Nat Publ Group"},{"key":"3851_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1586\/17469872.3.5.569","volume":"3","author":"B Zbytek","year":"2008","unstructured":"Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol. 2008;3:569\u201385.","journal-title":"Expert Rev Dermatol"},{"key":"3851_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02674-y","volume":"9","author":"M Werner-Klein","year":"2018","unstructured":"Werner-Klein M, Scheitler S, Hoffmann M, Hodak I, Dietz K, Lehnert P, et al. Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun. 2018;9:595.","journal-title":"Nat Commun"},{"key":"3851_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massagu\u00e9","year":"2016","unstructured":"Massagu\u00e9 J, Obenauf AC. Metastatic colonization. Nature. 2016;529:298.","journal-title":"Nature"},{"key":"3851_CR40","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","volume":"71","author":"D Drygin","year":"2011","unstructured":"Drygin D, Lin A, Bliesath J, Ho CB, O\u2019Brien SE, Proffitt C, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011;71:1418\u201330.","journal-title":"Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03851-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03851-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03851-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:03:51Z","timestamp":1783980231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03851-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":40,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2026,8,4]]}},"alternative-id":["3851"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03851-4","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal procedures were performed in accordance with the conditions approved by the Institutional Animal Care and Use Committee (IACUC) at the Pennsylvania State University College of Medicine. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS"}}]}}